高危肌层浸润性尿路上皮癌辅助纳武利尤单抗5年疗效及ctDNA结果
CheckMate 274研究5年随访显示,高危肌层浸润性尿路上皮癌根治术后辅助纳武利尤单抗较安慰剂持续改善无病生存,中位DFS 21.9 vs 11.0个月(HR 0.74)。探索性ctDNA分析提示基线ctDNA可识别复发高危患者,且该亚组获益更明显。
要点
- 辅助纳武利尤单抗在高危MIUC中5年DFS获益持续,安全性无新信号。
- PD-L1≥1%患者DFS获益更显著,中位55.5 vs 8.4个月(HR 0.58)。
- 基线ctDNA可检测者复发风险高,纳武利尤单抗在该亚组HR 0.35。
核心结论
- 5年结果证实高危MIUC术后辅助纳武利尤单抗具有持久的DFS获益和一致的安全性。
- 术后基线ctDNA检测可识别复发风险最高的患者,可能有助于指导辅助治疗策略,尚需进一步验证。
研究设计与样本
- III期随机双盲多中心CheckMate 274试验,比较辅助纳武利尤单抗与安慰剂。
- 709例高危MIUC根治术后患者1:1随机,纳武利尤单抗240 mg或安慰剂每2周,≤1年。
- 主要终点DFS,OS为关键次要终点;基线ctDNA采用Signatera assay进行事后探索性分析。
主要发现
- 所有随机患者中位DFS:纳武利尤单抗21.9个月(95%CI 18.8-36.9)vs 安慰剂11.0个月(95%CI 8.3-16.6),HR 0.74(95%CI 0.61-0.90)。
- PD-L1≥1%患者中位DFS:纳武利尤单抗55.5个月(95%CI 25.8-66.5)vs 安慰剂8.4个月(95%CI 5.6-20.0),HR 0.58(95%CI 0.42-0.79)。
- 所有随机患者中位OS:纳武利尤单抗75.0个月(95%CI 56.7-不可估计)vs 安慰剂50.1个月(95%CI 38.0-72.1),HR 0.83(95%CI 0.67-1.02)。
- 可评估患者中基线ctDNA检测出54/133(40.6%);基线ctDNA不可测vs可测中位DFS 52.1个月(95%CI 19.4-不可估计)vs 5.0个月(95%CI 2.8-6.5),HR 0.30(95%CI 0.18-0.48)。
- ctDNA可测患者中纳武利尤单抗vs安慰剂DFS HR 0.35(95%CI 0.18-0.66);ctDNA不可测患者HR 0.99(95%CI 0.51-1.93)。
临床怎么用
- 高危MIUC根治术后可考虑辅助纳武利尤单抗治疗,PD-L1≥1%者可能获益更明显。
- 术后基线ctDNA检测可用于识别复发高危患者,辅助治疗决策时可参考,但尚属探索性。
局限性
- ctDNA分析为事后探索性分析,样本量有限(133例可评估),需进一步验证。
- OS差异未达统计学显著,HR 0.83(95%CI 0.67-1.02)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Despite surgery, recurrence rates remain high in muscle-invasive urothelial carcinoma (MIUC). The phase III randomized, double-blind, multicenter CheckMate 274 trial comparing adjuvant nivolumab versus placebo in patients with high-risk MIUC after radical surgery demonstrated that adjuvant nivolumab improved disease-free survival (DFS) versus placebo. We report results with 5-year minimum follow-up including exploratory analyses of circulating tumor DNA (ctDNA). PATIENTS AND METHODS: Eligible patients had radical surgery (R0, with negative surgical margins) within 120 days before being randomized, with or without neoadjuvant cisplatin-based chemotherapy. Overall, 709 patients with MIUC at high risk of recurrence after surgery were randomly assigned 1:1 to nivolumab 240 mg or placebo every 2 weeks for ≤1 year. The primary endpoint was DFS. Overall survival (OS) was a key secondary endpoint. In a post hoc exploratory analysis, baseline ctDNA was measured using the Signatera assay. RESULTS: Median DFS was 21.9 months [95% confidence interval (CI) 18.8-36.9 months] with nivolumab versus 11.0 months (95% CI 8.3-16.6 months) with placebo in all randomized patients [hazard ratio (HR) 0.74, 95% CI 0.61-0.90], and 55.5 months (95% CI 25.8-66.5 months) versus 8.4 months (95% CI 5.6-20.0 months) in patients with tumor programmed death-ligand 1 expression ≥1% (HR 0.58, 95% CI 0.42-0.79). In all randomized patients, median OS was 75.0 months (95% CI 56.7 months-not estimable) with nivolumab versus 50.1 months (95% CI 38.0-72.1 months) with placebo (HR 0.83, 95% CI 0.67-1.02). Baseline ctDNA after radical surgery was detected in 54 (40.6%) of 133 assessable patients. Median DFS was 52.1 months (95% CI 19.4 months-not estimable) versus 5.0 months (95% CI 2.8-6.5 months) in patients with undetectable versus detectable ctDNA at baseline (HR 0.30, 95% CI 0.18-0.48). In patients included in the ctDNA analysis who had detectable ctDNA, the median DFS HR for nivolumab-treated patients versus placebo-treated patients was 0.35 (95% CI 0.18-0.66), while in patients with undetectable ctDNA, the HR for nivolumab-treated patients versus placebo-treated patients was 0.99 (95% CI 0.51-1.93). There were no new safety signals. CONCLUSIONS: Five-year results confirm durable DFS benefit and consistent safety profile for adjuvant nivolumab in high-risk MIUC. Post hoc exploratory ctDNA assessment identified patients at highest risk of recurrence and may inform tailored adjuvant therapy strategies, pending further validation.
引用
- Galsky MD, Gschwend JE, Milowsky MI, et al. Adjuvant nivolumab versus placebo for high-risk muscle-invasive urothelial carcinoma: 5-year efficacy and ctDNA results from CheckMate 274. Ann Oncol. 2025. PMID: 41110694. doi:10.1016/j.annonc.2025.09.139
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。